about
Treatment of medulloblastoma with a modified measles virusBiosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationAurora-A Kinase as a Promising Therapeutic Target in CancerConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsWhat next for newly diagnosed glioblastoma?A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057KIt is time to include patients with brain tumors in phase I trials in oncologyBioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.Phase II trial of gemcitabine in advanced sarcomas.Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.Vorinostat in solid and hematologic malignanciesPhase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group studyAurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells.Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.Converting tumor-specific markers into reporters of oncolytic virus infection.Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cellsPhase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBMInhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.Medical management of high-grade astrocytoma: current and emerging therapies.North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.Technology evaluation: Allovectin-7, Vical.Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasionVertebra plana caused by primary Ewing sarcoma: case report and review of the literature.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samplesBrain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomasValidation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastomaEffective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
P50
Q24602003-988F80F3-7540-4492-A769-785D71C30453Q26700080-375C6BB8-40A1-4F81-9488-A72158C1A86DQ26771371-05DA5BF0-3352-4896-AFA9-22C9387DCA67Q26801351-285DC8DF-DF83-415D-907C-1A012816F852Q28086839-ED270A71-59DC-44E9-8AD1-A5663E96EB7DQ30301096-26B9199E-A048-4B77-AC94-571FD453F514Q30359570-B4ACE51B-7588-4058-8272-4349DD73468BQ30443237-8B035139-5A97-46D3-809F-FCF6D84A6FEBQ30496489-EEF67BE0-6CE6-450C-BD14-6D17AC841DC6Q33343208-217CAB66-7434-471B-9D9C-12352CE3DDF7Q33382342-708F6E40-1192-48A7-AEAD-756B829B16A1Q33383828-92936A04-507D-4632-9CE9-F57836E467C6Q33385544-A64F1E10-3771-4214-AA5C-858379F94F69Q33398291-973C417D-893A-4971-A654-84FEA35FED15Q33591225-2786A1B0-BA3C-495F-A6D1-DBB9D0B7D26AQ33605148-A2A3251E-457B-47B8-9310-DF87DD3DBB42Q33713865-08B593B7-C6CF-49C5-AD31-EBFF2360A20AQ33759701-B4C9ECDD-2A40-4149-8DEB-86010785D4E1Q33932032-F710DE13-1209-4CED-A7DC-A094EE25808CQ33962175-340EEF76-B812-4FC9-B49A-1A14307A2D40Q34000650-57157A68-CF98-4B28-BDDE-BC5769AE0BB7Q34436053-4A745F57-BF87-4583-A5EC-01584A4D3C24Q34441838-C5A2EDCD-539D-4E09-8A55-D157DDD710C3Q34470472-AF1B2011-192D-40E9-892D-7CE2BAAEFC57Q34554887-B3865F59-7A22-4A13-AA6F-73E9BD10C71CQ34606869-453E5E1D-E24B-4C3B-A540-B3FF2E09D705Q34752074-A1CB38FD-8750-45D7-B09C-8023F2900260Q34763999-5A0C91D8-699D-48C3-9058-627D9927A112Q34886822-EBF851DE-1ED9-4DF1-8309-0729C3D67D62Q35034285-411FAD3F-A89F-4801-8154-8C71D14B768EQ35096934-905D15D4-CFA1-4D6C-8101-AAABC44E98D1Q35161909-A2936907-009B-404A-B098-D28924EE4077Q35226511-BBC1D0F0-34FE-4AAC-B095-BFC5DD05DC06Q35234338-B033FAD7-5D5A-447D-B7CE-2CC7FDA6B1A8Q35800569-4C04E51F-5DA7-43D9-8A5D-E080427B2CFDQ35845219-5C62BCD0-E17B-40BF-AED6-2A64D7C90CE9Q35892063-4C65CD94-C412-43AC-B9BB-39A2387C32EFQ36014057-388A9BDC-7784-4C16-8E11-058E1D114272Q36113188-A339F2A0-33F4-4802-9CDA-3B9AF9416958Q36298608-978D17C2-8AB8-4E68-8C33-6EFC9848583D
P50
name
Evanthia Galanis
@en
type
label
Evanthia Galanis
@en
prefLabel
Evanthia Galanis
@en